Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC
Cardiol Therapeutics entered into an at-the-market equity offering agreement with Jefferies LLC allowing it to sell up to US$75 million of common shares from time to time at prevailing market prices on Nasdaq. Sales under the program are discretionary, with proceeds earmarked for CardiolRx development in recurrent pericarditis — including a New Drug Application pending Phase III MAVERIC trial outcomes — plus CRD-38 clinical development and general corporate expenses.
Key figures
- Deal Value Usd
- 75000000
- Sales agent
- Jefferies LLC
- Program type
- at-the-market (ATM) equity program
- Max shares value usd
- 75000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.